Shire eyes Europe with UCB drug buy

In nabbing rights to UCB's attention deficit Equasym drugs, Shire has built a bridge into Europe, a market the company hasn't yet mined for ADHD riches. Release l Report 

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.